Publication of prospectus regarding the rights issue in Senzime and application for listing on Nasdaq First North
The prospectus has been approved and registered by the Swedish Financial Supervisory Agency (“SFSA”) March 13 2017. The subscription period in the rights issue takes place from and including March 14, 2017 to and including March 28, 2017. The rights issue of approximately SEK 24.4 million before issue costs is fully guaranteed through subscription undertakings and guarantees from Senzime’s principal owners.
The prospectus regarding the rights issue in Senzime is now available on Senzime’s website (www.senzime.com) and on Redeye’s website (www.redeye.se). The prospectus will also be available on the SFSA’s website (www.fi.se).
"Now Senzime takes another big step towards the market. We have begun the commercialization of our product portfolio and aim to build a world-leading company in the peri- and post-operative patient monitoring. In recent months, we have signed a breakthrough agreement for the Japanese market, strengthened our organization and have ongoing discussions with potential license partners on additional markets. We face several CE markings and a broad market introduction in 2017. Growth capital will create conditions to accelerate the global commercialization of our product portfolio," says Lena Söderström, CEO of Senzime.
Senzime’s board has now applied for listing on Nasdaq First North, and the first day of trading is expected to be April 11, 2017.
For further information, please contact:
Lena Söderström, CEO of Senzime AB
Tel: +46 708-16 39 12, email: firstname.lastname@example.org
TO THE EDITORS
Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on AktieTorget (ATORG: SEZI) www.senzime.com
The information in this press release is not an offer to acquire, subscribe for or otherwise trade in shares, subscription rights or other securities in Senzime, neither from Senzime or from anyone else. An invitation to subscribe for shares in Senzime will only be made through the prospectus that has been published and made available at e.g. Senzimes website. The prospectus contains risk factors, financial information and information about Senzimes board. This press release has not been approved by any regulatory authority and is not a prospectus. Investors should not subscribe for or purchase any securities on the basis of the information in this press release but on the basis of the information contained in the prospectus.
Neither the prospectus or the information in this press release may be released, published or distributed in the United States, Canada, Australia, Hong Kong, Japan, New Zealand or South Africa or any other country or any jurisdiction where such action or the offer requires registration or measures other than those under Swedish law.